Fig. 1From: Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysisLandmark analysis according to the presence of irAEs. Kaplan–Meier curves with the threshold of 120 days (landmark analysis) for progression-free survival. Abbreviations: irAEs, immune-related adverse events; HR, hazard ratioBack to article page